Focus: Bicara Therapeutics is a Boston-based public biotech company specializing in dual-action biologics and antibodies, primarily focused on oncology indications. The company operates at a mid-cap scale with a focused pipeline in head and neck squamous cell carcinoma.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Growing — net +15 jobs in 30d
16 jobs added vs 1 removed. Steady team buildout.
Bicara is a speculative play for oncology specialists willing to tolerate pre-revenue risk in exchange for pipeline catalysts and public equity upside.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Bicara Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bicara Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+1 more
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX) The Globe and Mail
BCAX News | BICARA THERAPEUTICS INC (NASDAQ:BCAX) - ChartMill
BCAX News | BICARA THERAPEUTICS INC (NASDAQ:BCAX) ChartMill
Bicara Therapeutics Inc. presents breakthrough in EGFR-targeted therapy for HPV-negative HNSCC - Traders Union
Bicara Therapeutics Inc. presents breakthrough in EGFR-targeted therapy for HPV-negative HNSCC Traders Union
Bicara Therapeutics Inc. launches FORTIFI clinical trial targeting 1L R/M HPV negative HNSCC patients - Traders Union
Bicara Therapeutics Inc. launches FORTIFI clinical trial targeting 1L R/M HPV negative HNSCC patients Traders Union
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Bicara Therapeutics Inc. (BCAX) The Globe and Mail
New data from Bicara Therapeutics Inc. reveals long term outcomes from HPV negative HNSCC trial - Traders Union
New data from Bicara Therapeutics Inc. reveals long term outcomes from HPV negative HNSCC trial Traders Union
Showing 6 of 10 news items
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo